Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness
Titel:
Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness
Auteur:
Woods, Beth S. Sideris, Eleftherios Sydes, Matthew R. Gannon, Melissa R. Parmar, Mahesh K.B. Alzouebi, Mymoona Attard, Gerhardt Birtle, Alison J. Brock, Susannah Cathomas, Richard Chakraborti, Prabir R. Cook, Audrey Cross, William R. Dearnaley, David P. Gale, Joanna Gibbs, Stephanie Graham, John D. Hughes, Robert Jones, Rob J. Laing, Robert Mason, Malcolm D. Matheson, David McLaren, Duncan B. Millman, Robin O'Sullivan, Joe M. Parikh, Omi Parker, Christopher C. Peedell, Clive Protheroe, Andrew Ritchie, Alastair W.S. Robinson, Angus Russell, J. Martin Simms, Matthew S. Srihari, Narayanan N. Srinivasan, Rajaguru Staffurth, John N. Sundar, Santhanam Thalmann, George N. Tolan, Shaun Tran, Anna T.H. Tsang, David Wagstaff, John James, Nicholas D. Sculpher, Mark J.